Cancer Research and Treatment10.4143/crt.2017.4912019511169-177The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic ChemotherapyJi Young Choi, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Seong Jin Jo,,
Clinical Lung Cancer10.3816/clc.2008.n.021200893141-143Monoclonal Antibodies Versus Tyrosine Kinase Inhibitors Concurrent with Chemotherapy in Non–Small-Cell Lung Cancer: Exploring Divergent ResultsPrimo N. Lara, Suresh S. Ramalingam,
Medical Oncology10.1007/s12032-014-0473-y2015322Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysisLi Sun, Jie-Tao Ma, Shu-Ling Zhang, Hua-Wei Zou, Cheng-Bo Han,,
Journal of Thoracic Oncology10.1097/01.jto.0000283512.51667.bd200728S509P2-048: Activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in chemotherapy-pretreated non-small cell lung cancer (NSCLC) patients (pts) prospectively selected according to specific molecular predictive factorsCarmen Nuzzo,
Lung Cancer10.1016/0169-5002(90)90352-m199061-258Chemotherapy of advanced non-small-cell lung cancer: A randomized trial of three cis-platin-based chemotherapy regimens,
Annals of Oncology10.1016/j.annonc.2020.10.402202031S1402408P Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutationJ. Maevskaya, K. Laktionov, D. Yudin, L. Vladimirova,
Radiology and Oncology10.1515/raon-2017-00292017513241-251Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitorsMatjaz Zwitter, Antonio Rossi, Massimo Di Maio, Maja Pohar Perme, Gilberto Lopes,
Lung Cancer10.1016/s0169-5002(87)80502-019873150Comparison of alternating to nonalternating chemotherapy regimens for non-small cell lung cancer,
Scientific Reports10.1038/srep36371201661EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutationJianlin Xu, Haitang Yang, Bo Jin, Yuqing Lou, Yanwei Zhang, Xueyan Zhang, Hua Zhong, Huiming Wang, Dan Wu, Baohui Han,,
Lung Cancer10.1016/0169-5002(96)84345-51995133350A randomised trial of two cisplatin-containing chemotherapy regimens in patients with Stage III-B and IV non-small cell lung cancer,